Since the 1980s, transcranial magnetic stimulation has been used to study the nerve fibers that carry information about movements from the brain to the spinal cord and on to the muscles. In the late 1990s, physicians began to explore the therapeutic potential of transcranial magnetic stimulation for the treatment of a variety of diseases, with depression being the most thoroughly studied to date. Since then, more than 20 randomized, controlled trials studying transcranial magnetic stimulation as a treatment for depression have been published by investigators throughout the world.
NeuroStar TMS (transcranial magnetic stimulation) Therapy was FDA-cleared in October 2008 for patients suffering from depression who have not achieved satisfactory improvement from prior antidepressant medications. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. TMS Therapy is a short outpatient procedure, performed in your psychiatrist’s office under his or her supervision while you remain awake and alert. The typical initial course of treatment is about 19-37 minutes, depending on what the doctor determines is the correct protocol, daily over 4-6 weeks.
About NeuroStar TMS Therapy
The NeuroStar TMS (transcranial magnetic stimulation) Therapy system, developed by Neuronetics, is the first and only non-systemic and non-invasive depression treatment cleared by the US Food and Drug Administration (FDA) for patients who have not benefited from prior antidepressant treatment.
NeuroStar TMS Therapy is:
- Non-invasive, meaning that it does not involve surgery. It does not require any anesthesia or sedation, as the patient remains awake and alert during the treatment.
- Non-systemic, meaning that it is not taken by mouth and does not circulate in the bloodstream throughout the body.